NCT04857983CompletedPhase 2/3
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocial disability. We hypothesize that medications that specifically target sensory information processing deficits, rather than psychotic symptoms per se, will significantly enhance the benefits of a sensory-based targeted cognitive training (TCT) intervention in patients with schizophrenia. We will complete a randomized, double-blind clinical trial to: 1) confirm that the drug memantine augments TCT learning; 2) determine whether memantine enhances the clinical benefits from a full 30 session course of TCT vs. TCT plus placebo in antipsychotic- medicated schizophrenia patients, and 3) determine if memantine's enhancement of TCT is most effective in biomarker-defined subgroups of patients.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 62 (actual)
- First submitted
- 21 Apr 2021
- Start date
- 6 Jul 2021
- Primary completion date
- 30 Mar 2025
- Lead sponsor
- University of California, San Diego
- Diseases
- Schizophrenia
- NCT number
- NCT04857983
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 62
- From 6 Jul 2021 to the primary completion date, 30 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A history of traumatic brain injury
Other
- Meets DSM-IV criteria for current substance abuse or dependence and has been substance abstinent for less than 30 days
- Auditory or visual impairments severe enough to prevent study participation
- Under conservatorship (determined by Anasazi)
- Pregnancy
Who the study is looking for
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder
- Written informed consent to participate in the study
- Age 18-65
- Absence of dementia or mental retardation
- Urine toxicology negative for recreational drugs
- Fluent and literate in English
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Teaching Facility (CTF B-403 at UCSD Medical Center) Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.